Pneumovirus Infections: Clinical Trials

303 trials for Pneumovirus Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

199 completed, 23 recruiting, 22 terminated, 21 unknown. 105 Phase 1, 80 Phase 2, 46 Phase 3, 15 Not applicable, 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 1105Completed 81, Terminated 7, Active not recruiting 6, Recruiting 5, Withdrawn 3, Unknown 2, Not yet recruiting 1
Phase 280Completed 55, Recruiting 9, Terminated 8, Active not recruiting 4, Withdrawn 2, Not yet recruiting 1, Unknown 1
Phase 346Completed 30, Recruiting 6, Terminated 5, Active not recruiting 4, Withdrawn 1
Not applicable15Completed 10, Unknown 3, Recruiting 1, Terminated 1
Phase 43Completed 2, Not yet recruiting 1

Follow Pneumovirus Infections: new trials by email Literature Review of Pneumovirus Infections trials Research Report on Pneumovirus Infections

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults
Bivalent RSV Vaccine (IN006), Placebo - Respiratory Syncytial Virus Infections
Phase 1Not yet recruitingShenzhen Shenxin Biotechnology Co., Ltd2002026-12-012026-04-13
Severe Pediatric Respiratory Syncytial Virus Infections Occurring in the Era of Antiviral Prophylaxis
Prior exposure to prophylactic treatment with Abrysvo or nirsevimab/clesrovimab, Non-exposure to prior prophylactic treatment - Children <24 Months Hospitalized for RSV-related Lower Respiratory Tract Infection
Not yet recruitingAssistance Publique - Hôpitaux de Paris3002026-11-152026-10-26
Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection.
SYH2066, Placebo - Respiratory Syncytial Virus Infections
Phase 2Not yet recruitingCSPC Ouyi Pharmaceutical Co., Ltd.802026-11-132026-10-20
Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region
Vaccination Coverage Among Pregnant Women
Not yet recruitingAssistance Publique - Hôpitaux de Paris16052026-11-012026-10-20
Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset
ABRYSVO - Respiratory Syncytial Virus Infections
Not yet recruitingPfizer12026-10-152026-09-24
The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation
Clesrovimab - RSV Infection
Phase 4Not yet recruitingEmory University242026-09-012026-09-17
Internal Jugular Vein Respiratory Variability as a Marker of Disease Severity in Infant Bronchiolitis
Point-of-Care Ultrasonography - Acute Bronchiolitis, Viral Bronchiolitis
Not yet recruitingEskisehir Osmangazi University1202026-09-012026-08-21
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
zelicapavir, Placebo - RSV Infection, RSV
Phase 2RecruitingEnanta Pharmaceuticals, Inc1502026-07-092026-07-20
Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections
SARS CoV 2 Infection, RSV Infections
Not yet recruitingFabiana Sherine Ganem dos Santos1502026-07-012026-06-11
Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.
Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant) - Respiratory Syncytial Virus Infections
Phase 1 / Phase 2RecruitingAb&B Bio-tech Co., Ltd.JS4702026-05-142026-05-27
Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France
saliva sampling, Nasopharyngeal swab - Respiratory Tract Infections (RTI), Influenza -Like Illness
RecruitingInstitut National de la Santé Et de la Recherche Médicale, France250002026-05-142026-08-03
Risk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University Hospital
Bronchiolitis, Acute Bronchiolitis
Not yet recruitingAssiut University652026-05-012026-04-01
Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age
H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3 - Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
Phase 1RecruitingSanofi5702026-04-152026-05-08
Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants
Respiratory Syncytial Virus Infection, Bronchiolitis
Not yet recruitingPhuc Huu Phan2502026-04-012026-02-18
A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children
SIM0916, SIM0916 Placebo - Respiratory Syncytial Virus Infection
Phase 3RecruitingSimcere Pharmaceutical Co., Ltd4982026-03-112026-04-02
A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.
Ziresovir (AK0529), Placebo - Respiratory Syncytial Virus Infections
Phase 2 / Phase 3RecruitingShanghai Ark Biopharmaceutical Co., Ltd.2902026-03-032026-06-22
RSV-Positive Children <5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSV
Respiratory Syncytial Virus Infection, Acute Bronchiolitis Due to Respiratory Syncytial Virus
Not yet recruitingEskisehir Osmangazi University40002026-01-012026-01-16
Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá
RSVpreF vaccine (Abrysvo) and Nirsevimab (Beyfortus) or unexposed - Respiratory Syncytial Virus Infections, Severe Acute Respiratory Infection
Active not recruitingBogotá District Health Secretariat10972026-01-012026-08-06
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Remdesivir, Survey Administration, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease
Phase 2RecruitingFred Hutchinson Cancer Center602025-12-232026-10-01
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
S-337395, Placebo - Respiratory Syncytial Virus Infections
Phase 2RecruitingShionogi1922025-12-112026-10-21

Showing 20 of 303. Sign in to see all of them.

Narrower conditions

Respiratory Syncytial Virus Infections (303)  ·  Respiratory Tract Infections (18)  ·  Influenza, Human (17)  ·  COVID-19 (16)  ·  Bronchiolitis (15)  ·  Virus Diseases (11)  ·  Infections (9)  ·  Pneumonia (7)  ·  Asthma (6)  ·  Paramyxoviridae Infections (4)  ·  Premature Birth (4)  ·  Bronchiolitis, Viral (3)  ·  Bronchopulmonary Dysplasia (3)  ·  Respiratory Sounds (3)  ·  Whooping Cough (3)

Broader conditions

Mononegavirales Infections (303)  ·  RNA Virus Infections (302)  ·  Paramyxoviridae Infections (299)  ·  Infections (294)  ·  Virus Diseases (292)  ·  Respiratory Tract Diseases (59)  ·  Lung Diseases (39)  ·  Respiratory Tract Infections (37)  ·  Bronchial Diseases (20)  ·  Lung Diseases, Obstructive (19)  ·  Coronaviridae Infections (17)  ·  Nidovirales Infections (17)  ·  Orthomyxoviridae Infections (17)  ·  Bronchitis (16)

Interventions

Saline Solution (9)  ·  EDP-938 (8)  ·  nirsevimab (8)  ·  Palivizumab (7)  ·  sisunatovir (7)  ·  ziresovir (7)  ·  4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (6)  ·  JNJ-53718678 (5)  ·  abrysvo (5)  ·  presatovir (5)  ·  Adjuvants, Pharmaceutic (4)  ·  Midazolam (4)  ·  Respiratory Syncytial Virus Vaccines (4)  ·  gontivimab (4)  ·  motavizumab (4)

Sponsors

GlaxoSmithKline (39)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (23)  ·  Enanta Pharmaceuticals, Inc (14)  ·  Pfizer (13)  ·  MedImmune LLC (10)  ·  Sanofi Pasteur, a Sanofi Company (9)  ·  Gilead Sciences (8)  ·  Shanghai Ark Biopharmaceutical Co., Ltd. (7)  ·  Alios Biopharma Inc. (5)  ·  Bavarian Nordic (5)  ·  Hospices Civils de Lyon (5)  ·  AbbVie (prior sponsor, Abbott) (4)  ·  Ablynx, a Sanofi company (4)  ·  Assistance Publique - Hôpitaux de Paris (4)  ·  AstraZeneca (4)

Countries

United States (143)  ·  United Kingdom (53)  ·  Australia (43)  ·  Spain (38)  ·  France (31)  ·  Canada (30)  ·  China (30)  ·  Belgium (28)  ·  Japan (28)  ·  South Africa (27)  ·  Germany (24)  ·  Poland (22)  ·  Finland (21)  ·  Italy (20)  ·  Argentina (18)

Top investigators

Ruth A. Karron, MD (9)  ·  Oliver Medzihradsky, MD MPH MS (3)  ·  Coleen Cunningham, MD (2)  ·  D. Nigel Thomas, Ph.D. (2)  ·  Genevieve Losonsky, MD (2)

Results publications

PMID 31951765, PMID 34774184, PMID 38921800, PMID 29401325, PMID 29509911, PMID 29509929, PMID 31211158, PMID 37468530, PMID 38902186, PMID 14722149, PMID 15188713, PMID 15356783, PMID 16390959, PMID 17156899, PMID 17541638, PMID 18477402, PMID 18676537, PMID 19196675, PMID 19782998, PMID 20008423, PMID 20492042, PMID 20525274, PMID 20851929, PMID 21318606, PMID 21343842, PMID 21926667, PMID 22203430, PMID 22335500, PMID 22354452, PMID 22546928, PMID 22553238, PMID 22943074, PMID 23089688, PMID 23153449, PMID 23734183, PMID 23861694, PMID 23989104, PMID 24080520, PMID 24086113, PMID 24367040, PMID 24799541, PMID 24941423, PMID 25140957, PMID 25714161, PMID 25970287, PMID 26227333, PMID 26237402, PMID 26268313, PMID 26510727, PMID 26580997

NIH funding

2023 (9), 2019 (6), 2014 (5), 2016 (5), 2018 (5), 2015 (2), 2017 (2), 2025 (1), 5UM1AI148684-04 (1), R01AI179874 (1), R01HD105678 (1)